Liquid biopsies, in particular, analysis of cell-free DNA (cfDNA), have emerged as a
promising noninvasive diagnostic approach in oncology. Abnormal distribution of DNA …

Analysis of circulating nucleic acids in bodily fluids, referred to as “liquid biopsies”, is rapidly
gaining prominence. Studies have shown that cell-free DNA (cfDNA) has great potential in …

Liquid biopsy, a minimally invasive approach, is a highly powerful clinical tool for the real‐
time follow‐up of cancer and overcomes many limitations of tissue biopsies. Epigenetic …

Liquid biopsy based on cell-free DNA (cfDNA) enables non-invasive dynamic assessment of
disease status in patients with cancer, both in the early and advanced settings. The analysis …

Background Targeted methylation sequencing of plasma cell-free DNA (cfDNA) has a
potential to expand liquid biopsies to patients with tumors without detectable oncogenic …

Background Analysis of circulating tumor DNA has become increasingly important as a tool
for cancer care. However, the focus of previous studies has been on short fragments of DNA …

Lung, breast, colorectal, and prostate cancers are the most incident worldwide. Optimal
population-based cancer screening methods remain an unmet need, since cancer detection …

DNA methylation-based epigenetic signatures have become valuable cancer biomarkers.
We highlight the advantages of liquid biopsy based DNA-methylation profiling for …

Lung cancer is the leading cause of cancer-related deaths worldwide. Recent
implementation of low-dose computed tomography (LDCT) screening is predicted to lead to …

DNA methylation profiles are in dynamic equilibrium via the initiation of methylation,
maintenance of methylation and demethylation, which control gene expression and …